PDCD1 and Haim-Munk syndrome: Programmed cell death protein 1 (PD-1) inhibitor, programmed cell death ligand 1 (PD-L1) inhibitor, and other ICIs have shown promising results in numerous pre-clinical and clinical trials for the treatment of HMs.